Colon Cancer: Practice Essentials, Background, Pathophysiology

Practice Essentials

Colon cancer is the most mutual type of gastrointestinal cancer. It is a multifactorial disease physical process, with etiology encompassing genetic factors, environmental exposures (including diet), in addition to inflammatory weather condition of the digestive tract.

Surgery currently is the definitive treatment modality. [1] The image below depictscriterion colectomies for adenocarcinoma of the colon.

Standard colectomies for adenocarcinoma of the col Standard colectomies for adenocarcinoma of the colon.

Signs as well as symptoms

Colon cancer is instantly ofttimes detected during screening procedures. Common clinical presentations include the following:

  • Iron-deficiency anemia
  • Rectal bleeding
  • Abdominal pain
  • Change inwards bowel habits
  • Intestinal obstacle or perforation

Physical findings may include the next:

  • Early illness: Nonspecific findings (fatigue, weight loss) or none at all
  • More advanced illness: Abdominal tenderness, macroscopic rectal haemorrhage, palpable abdominal volume, hepatomegaly, ascites

SeePresentation for more detail.


Laboratory studies that may live helpful include the next:

  • Complete blood count
  • Chemistries too liver office tests
  • Serum carcinoembryonic antigen

Imaging studies that may facilitate staging include the next:

  • Chest radiography
  • Chest computed tomography
  • Abdominal barium study
  • Abdominal/pelvic CT
  • Contrast ultrasonography of the abdomen too liver
  • Abdominal/pelvic MRI
  • Positron emission tomography, including fusion PET-CT scan

Other procedures that may live warranted include the next:

  • Colonoscopy
  • Sigmoidoscopy
  • Biopsy of suspicious lesions
  • Double-contrast barium enema

SeeWorkup for more detail.


Surgery is the only curative modality for localized colon cancer (stage I-III). Surgical resection potentially provides the only curative choice for patients with express metastatic affliction inwards liver as well as/or lung (stage IV illness). Surgical options include the following:

  • Right hemicolectomy: For lesions in the cecum and correct colon
  • Extended correct hemicolectomy: For lesions inwards the proximal or middle transverse colon
  • Left hemicolectomy: For lesions in the splenic flexure too left colon
  • Sigmoid colectomy: For sigmoid colon lesions
  • Total abdominal colectomy with ileorectal anastomosis: For selected patients with hereditary nonpolyposis colon cancer, attenuated familial adenomatous polyposis, metachronous cancers inward split up colon segments, or sharp malignant colon obstructionswith unknown status of the proximal bowel

Other therapeutic options for patients who are not surgical candidates include the following:

  • Cryotherapy
  • Radiofrequency ablation
  • Hepatic arterial infusion of chemotherapeutic agents

Adjuvant (postoperative) therapy is used in selected patients with stage II colon cancer who are at high chance of recurrence, in addition to is criterion for stage III colon cancer. Regimens used forsystemic chemotherapy may include the next:

  • 5-Fluorouracil (5-FU)
  • Capecitabine
  • Oxaliplatin
  • Combinations of multiple agents (eg, capecitabine or 5-FU with oxaliplatin, FOLFOX, FOLFIRI, cetuximab or panitumumab with encorafenib)

Regimens used for adjuvant chemotherapy normally include 5-FU with leucovorin or capecitabine, either lonely or inwards combination with oxaliplatin.[2, 3, 4]

For metastatic colon cancer, systemic chemotherapy is touchstone, with neoadjuvant chemotherapy used to convert unresectable isolated liver metastases to resectable liver metastases. Biologic agents hold assumed a major role, typically as targeted therapy based on genetic analysis of the tumor.Biologic agents employed to care for colon cancer include the following:

  • Bevacizumab (Avastin)
  • Cetuximab (Erbitux)
  • Ipilimumab (Yervoy)
  • Nivolumab (Opdivo)
  • Panitumumab (Vectibix)
  • Pembrolizumab (Keytruda)
  • Ramucirumab (Cyramza)
  • Tucatinib (Tukysa)

See Treatment in addition toMedication for more than item.

For more than info, come across Colorectal Cancer Guidelines.

Go to Oncology Decision Point Colorectal Cancer for practiced commentary on handlingdecisions in addition to related guidelines.

For patient education info, meet Colon Cancer.

eMedicine Logo


Invasive colorectal cancer is a preventable affliction. Early detection through widely applied screening programs is the most importantelement inward the recent pass up of colorectal cancer in developed countries (encounter Overview/Epidemiology).

Fundamental advances in understanding the biology and genetics of colorectal cancer are taking home. This cognition is tardily making its agency into the clinic as well as being employed to improve stratify private risks of developing colorectal cancer, find improve screening methodologies, allow for meliorateprognostication, in addition to improve the ability to predict benefit from novel anticancer therapies.

In the yesteryear 10 years, an unprecedented advance in systemic therapy for colorectal cancer has dramatically improved outcome for patients with metastatic disease. Until the mid-1990s, the only approved agent for colorectal cancer was 5-fluorouracil. Since and so, new agents inwards a diversity of classes have get available, including the following:

  • Cytotoxic agents (eg, irinotecan,oxaliplatin) [5]
  • Oral fluoropyrimidines (ie, capecitabine)
  • Biologic agents (eg, bevacizumab, cetuximab, panitumumab, pembrolizumab, nivolumab) [1]
  • Most late, anti-angiogenic agents (ie, ziv-aflibercept, regorafenib)

Although surgery remains the definitive handling modality, these newagents volition probable translate into improved cure rates for patients with early-stage illness (stage II together with III) together with prolonged survival for those with stage IV disease. Further advances are likely to come up from the development of novel targeted agents as well as from amend integration of systemic therapy with other modalities such as operation, radiations therapy, too liver-directed therapies.

eMedicine Logo


Genetically, colorectal cancer represents a complex illness, as well as genetic alterations are oft associated with progression from premalignant lesion (adenoma) to invasive adenocarcinoma. Sequence of molecular and genetic events leading to transformation from adenomatous polyps to overt malignancy has been characterized past Vogelsteinin addition to Fearon. [6]

The early case is a mutation of APC (adenomatous polyposis factor), which was showtime discovered inwards individuals with familial adenomatous polyposis (FAP). The protein encoded past APC is of import inwards the activation of oncogene c-myc in addition to cyclin D1, which drives the progression to malignant phenotype. Although FAP is a rare hereditary syndrome accounting for only almost 1% of cases ofcolon cancer, APC mutations are very frequent inwards sporadic colorectal cancers.

Other of import genes inwards colon carcinogenesis include the KRAS oncogene, chromosome eighteen loss of heterozygosity (LOH) leading to inactivation of SMAD4 (DPC4), and DCC (deleted inwards colon cancer) tumor suppression genes. Chromosome arm 17p deletion and mutations affecting the p53 tumor suppressor cistron confer resistance to programmed jail cell deat—h (apoptosis) in addition to areidea to live belatedly events inward colon carcinogenesis.

A subset of colorectal cancers is characterized with deficient DNA mismatch repair. This phenotype has been linked to mutations of genes such as MSH2, MLH1, too PMS2. These mutations final result inwards hence-called high frequency microsatellite instability (H-MSI), which tin live detected with an immunocytochemistry assay. H-MSI is a hallmark of hereditary nonpolyposis colon cancer syndrome (HNPCC, Lynch syndrome), whichaccounts for about 6% of all colon cancers. H-MSI is likewise establish inward near 20% of sporadic colon cancers.

In add-on to mutations, epigenetic events such every bit abnormal deoxyribonucleic acid methylation can likewise cause silencing of tumor suppressor genes or activation of oncogenes. These events compromise the genetic balance in addition to ultimately Pb to malignant transformation.

Cancer cells make extracellular vesicles (EVs)—principally, microvesicles in addition to exosomes—that can promote the growth, survival,invasiveness, and metastatic activity of tumors. [7] Zhao et al reported that in an fauna model of aggressive late-stage colorectal cancer, tumor-secreted EVs promoted resistance to immune checkpoint blockade. The colorectal cancer cells in this model secrete exosomes that transport immunosuppressive microRNAs these block CD28 on T cells as well as CD80 on dendritic cells that infiltrate the tumors, disabling T-prison cell–mediated anti-tumorimmune reply. [8]

Further, these authors institute that intravenous injections of tumor-secreted exosomes without immunosuppressive microRNAs, inward combination with immune checkpoint inhibitors, resulted inwards an enhanced anti-tumor immune response. This offers a potential therapeutic strategy for tardily-stage colorectal cancer. [8]

eMedicine Logo


Colorectal cancer is a multifactorial disease physical process. Genetic factors, environmental exposures (including diet), in addition to inflammatory atmospheric condition of digestive tract are all involved inwards the evolution of colorectal cancer.

Although much most colorectal cancer genetics remains unknown, current research indicates that genetic factors have gotthe greatest correlation to colorectal cancer. Hereditary mutation of the APC cistron is the cause of familial adenomatous polyposis (FAP), inward which affected individuals transport an almost 100% adventure of developing colon cancer past age forty years.

Hereditary nonpolyposis colon cancer syndrome (HNPCC, Lynch syndrome) poseswell-nigh a twoscore% lifetime take a chance for developing colorectal cancer; individuals with this syndrome are also at increased risk for urothelial cancer, endometrial cancer, as well as other less common cancers. Lynch syndrome is characterized past deficient mismatch repair (dMMR) due to inherited mutation inwards 1 of the mismatch repair genes, such equallyhMLH1, hMSH2, hMSH6, hPMS1, hPMS2, in addition to mayhap other undiscovered genes.

HNPCC is a cause of nigh 6% of all colon cancers. Although the utilization of aspirin may trim back the chance of colorectal neoplasia inwards some populations, a study by Burn et al institute no issue on the incidence of colorectal cancer inward carriers of Lynch syndrome with employment of aspirin, resistant starch, or both. [ix]

Dietary factors are the field of studyof intense and ongoing investigations. [10] Epidemiologic studies have got linked increased adventure of colorectal cancer with a diet high inwards reddish meat together with animate being fat, depression-fiber diets, and low overall intake of fruits too vegetables. A study past Aune et al institute that a high intake of fiber was associated with a reduced hazard of colorectal cancer. In particular, cereal fiber as well as whole grains were found to live effective.[11] A study by Pala et al institute that high yogurt intake was too associated with a decreased run a risk for colorectal cancer. [12]

A cohort study by Tabung et al that followed 121,050 adults for 26 years establish that in both men as well as women, intake of proinflammatory diets (replete in scarlet, processed, in addition to organ meat, for representative) was associated with a significantlyhigher risk of developing colorectal cancer. Risk was especially high in overweight together with obese men as well as, paradoxically, inward lean women. Risk was likewise increased in men in addition to women who do non imbibe alcohol. [xiii]

Factors associated with lower gamble include folate intake, calcium intake, together with estrogen replacement therapy. However, most of these studies were retrospective epidemiologic studies and hold even so to live validated inwardprospective, placebo-controlled, interventional trials.

Obesity together with lifestyle choices such as cigarette smoking, alcohol consumption, and sedentary habits have likewise been associated with increased run a risk for colorectal cancer. A meta-analysis of prospective cohort studies institute a small-scale but pregnant elevation of colorectal cancer chance in current smokers; gamble was higher for men in addition to for rectal cancers thancolon cancers, as well as persisting in erstwhile smokers. [xiv]

In a big prospective study, Cho together with colleagues reported that high alcohol consumption was associated with elevated take chances for colorectal cancer, inward individuals with a family history of the illness. The association was significant only for the highest alcohol intake category of thirty g or more than daily; no meaning linear tendency was evident. In comparison with nondrinkerswith no family history, individuals who consumed thirty g/d or more than as well as who had a family history of colorectal cancer had a relative gamble for colon cancer of 2.fourscore. [fifteen]

Current screening guidelines recommend that clinicians live aware of increased colorectal cancer run a risk inwards patients who fume or are obese, but do not highlight the increased take a chance in patients with diabetes. A meta-analysis of case-command in addition to cohort studiesidentified diabetes every bit an independent adventure ingredient for colon too rectal cancer. Subgroup analyses confirmed the consistency of the findings across study type too population. This info may have got an impact on screening guidelines too on building adventure models of colorectal cancer. [16]

Association between body mass index (BMI) as well as hazard of colorectal adenomas too cancer has been reported, but few studies hold hadadequate sample size for conducting stratified analyses. Jacobs et al pooled information from 8,213 participants inward seven prospective studies as well as establish that BMI was significantly related to most histologic characteristics of metachronous adenomas in men but not in women. The researchers concluded that trunk size may affect colorectal carcinogenesis at comparatively early stages, peculiarly in men. [17]

A nationwide cohortstudy from France of incident colorectal cancer inwards obese patients, which compared outcomes inwards 74,131 patients who underwent bariatric surgical operation with 971, 217 patients who did non have surgical operation, plant that inward the bariatric surgical procedure cohort, risk of colorectal cancer was the same every bit that in the full general population. In the obese patients who did not undergo bariatric surgical process, the adventure was 34% above that of the full general population. [eighteen]

Activation of the WNT signaling pathway, which most oftentimes results from APC loss, plays a critical role inwards the evolution of colorectal cancer, in addition to CTNNB1 (β-catenin) is a major mediator of the WNT pathway. WNT-CTNNB1 signaling also appears to live involved inward obesity, glucose metabolism, together with metabolic diseases such every bit obesity in addition to type II diabetes. Consequently, Morikawa et al hypothesized that the association of obesity as well as physical activity with colorectal cancer risk powerdiffer past tumor subtypes according to CTNNB1 status. [nineteen]

Using a molecular pathological epidemiology database, these researchers determined that take a chance of CTNNB1-negative cancer was significantly higher with greater BMI in addition to lower with increased physical activity flat. These researchers institute no association between either BMI or physical activity level as well as CTNNB1-positive cancer run a risk.[nineteen]

Greater adult-attained meridian is associated with an increased risk of colorectal cancer too adenoma, according to a systematic review in addition to meta-analysis by Zhou et al that included 47 observational studies involving 280,644 colorectal cancer and 14,139 colorectal adenoma cases.The study establish that overall, the gamble of colorectal cancer is 24% higher in the tallest individuals within the highest percentile of meridian,compared with the shortest individuals inside the lowest percentile. Every 3.ix-inch (10-centimeter) increment in elevation was associated with a 14% higher adventure for colon cancer as well as 6% higher odds of adenoma. Zhou et al recommend considering pinnacle equally a take a chance factor for colorectal cancer screening. [20]

Excessive consumption of beverages sweetened with high-fructose corn syrup (HFCS) is associated with increased take chances ofcolorectal cancer. In a study of adenomatous polyposis coli (APC) mutant mice, which are predisposed to train intestinal tumors, daily administration of 20 g of weight-adjusted HFCS (the equivalent of 1 soda a twenty-four hour period) resulted in a substantial increase inwards in polyps that apace developed into advanced, high-level dysplastic lesions. Carbon labeling showed uptake inward fructose inside the intestinal tumors themselves. Within the tumors, fructose was converted to fructose-1-phosphate, leading toactivation of glycolysis together with increased synthesis of fatty acids that back up tumor growth. [21]

Inflammatory bowel diseases such as ulcerative colitis too Crohn diseasetoo increment the take a chance of developing colorectal adenocarcinoma. The chance for developing colorectal malignancy increases with the duration of inflammatory bowel illness together with the greater extent of colon interest.

A matched example-control study of incident colorectal cancer cases inward the United Kingdom of Great Britain and Northern Ireland from 1989 to 2012 plant that utilisation of oral antibiotics was associated with increased adventure of colon cancer, peculiarly in the proximal colon. The association involved antibiotic exposureoccurring more than than 10 years before colon cancer diagnosis. Risk was dose dependent but was observed later on fifty-fifty a unmarried class of antibiotics. In improver, take chances was greatest with anti-anaerobic antibiotics. The authors banker’s bill that such antibiotics markedly disrupt the gut microbiome, which consists predominantly of anaerobes, too this disruption may facilitate the acquisition or evolution of a carcinogenic colon microbiota. [22]

eMedicine Logo


The incidence as well as mortality from colon cancer have got been on a ho-hum decline over the past several decades in the the States, with the incidence falling on average 2.4% each year together with death rates falling on average 2.2% each yr over 2007-2019.[23]  However, colorectal cancers stay the 3rd most mutual cancer and 3rd most common cause of cancer-related mortality inward US men in addition to women. [24]  In add-on, rates of colon cancer in younger persons hold been increasing. [25]

The American Cancer Society estimatesthat 106,970 novel cases of colon cancer will be diagnosed inwards the USA inward 2023. Estimates for mortality from colon as well as rectal cancer (the 2 are combined because of classification difficulties) are for 52,550 deaths in 2023. [24]

A instance-control study using national Veterans Affairs–Medicare information concluded that colonoscopy was associated with pregnant reductions inward colorectal cancer mortality inwards veterans.Mortality benefit was greater for left-sided cancer than right-sided cancer. [26] Case patients (n= 4964) were veterans aged 52 years or older who were diagnosed with colorectal cancer inwards 2002 to 2008 and died of the illness by the end of 2010. Case patients were matched to four command patients (n= 9,856) without prior colorectal cancer. Risk of mortality from left-sided cancer was reduced in those who had undergonecolonoscopy (odds ratio [OR], 0.28 [CI, 0.24 to 0.32]), equally was hazard for mortality from correct-sided cancer (OR, 0.54 [CI, 0.47 to 0.63]). [26]

Worldwide, an estimated 1,931,590 novel cases of colorectal cancer occurred in 2020 (10% of all cancers). Geographically, the incidence varies as much equally 6-crimp. The highest estimated rates are inward southern Europe (per 100,000 population, 40.6 inwards men as well as 24.5 inwards women), too thelowest in due south-fundamental Asia (per 100,000 population, 6.6 in men together with 4.4 in women). [27]

Worldwide, colorectal cancer caused close to 935,173 deaths inward 2020, accounting for nine.4% of cancer mortality overall. As with incidence rates, mortality rates worldwide vary six-crimp, with the highest estimated mortality rates  in key too eastern Europe (xiv.5 per 100,000 population), in addition to the lowest inward south-keyAsia (3.2 per 100,000 population). [27]

An epidemiologic study from the European Union (European Union) concluded that inward 2018, colorectal cancer would account for the minute highest number of cancer deaths, at 98,000 deaths in men together with 79,400 inward women. However, while the total number of colorectal deaths in the European Union has risen since 2012 because of the aging population, since 2012 the age-standardized death rate has fallen by 6.7% (to15.8 per 100,000 in men together with 7.5% (to 9.2 per 100,000) inwards women. [28]

Racial, sexual, together with age-related disparities inward incidence

Since 1989, colorectal cancer incidence rates have got been higher for Blacks than for Whites in both men in addition to women. Currently, incidence rates of colorectal cancer are 21% higher in Black men as well as 18% higher inwards Black women compared with White men too women, respectively.[29]

Colorectal mortality rates are 44% higher in Black men in addition to 31% higher in Black women compared with White men together with women. However, from 2010 to 2019, colorectal cancer expiry rates declined faster in Blacks than inward Whites (2.8% vs 1.8% per yr), narrowing the racial disparity in both men as well as women. [29]

Asians/Pacific Islanders hold thelowest incidence as well as mortality from colorectal cancer. Hispanics have the moment lowest. [23]

The incidence of colorectal cancer is relatively equal inwards men too women. The American Cancer Society estimates that colon cancer volition live diagnosed in 54,420 men too 52,550 women in the U.S.A. in 2023. [24]

Age is a well-known adventure ingredient forcolorectal cancer, equally it is for many other solid tumors. The timeline for progression from early premalignant lesion to malignant cancer ranges from 10-20 years. Median age at diagnosis is 66 years. [23]

However, in contrast to the pass up in colon cancer incidence rates inwards persons historic period 55 in addition to older, which began in the mid-1980s, rates of colon cancer in younger persons hold been increasing. In adults age 20 to 39 years,colon cancer incidence rates have got increased by 1.0% to 2.4% annually since the mid-1980s; inward those historic period 40 to 54 years, the incidence has increased past 0.5% to 1.3% annually since the mid-1990s. Currently, adults born circa 1990 have got double the adventure of colon cancer compared with those born circa 1950. Increased obesity is 1 likely factor. [25]

From 2011 through 2016, the incidence of colorectal cancer continued todecline inwards those aged 65 years as well as older, past 3.3% annually. Rates increased past 1% annually inwards those aged 50 to 64 years, and rose more or less 2% annually inward those younger than 50 years. The American Cancer Society estimated that 17,930 of the 147,950 individuals expected to be diagnosed with colon together with rectal cancer inward 2020, as well as 3640 of the 53,200 expected to exit from the affliction, would live younger than 50 years of age.[xxx]

Tumor site tends to vary past patient historic period. From 2012 to 2016, the proximal colon was the site of colon cancer inward 23% of those under 50 years of historic period, 31% of those 50-64 years, in addition to 49% of those 65 together with older. Incidence trends varied by race/ethnicity: inwards those 50-64 years old, rates increased in whites past 1.3% per year but decreased in blacks by 1.6% per year, and were stable in Hispanics. In those youngerthan 50, rates rose by 2% annually inward whites and by 0.5% annually in Blacks. [thirty]

A review of Surveillance, Epidemiology in addition to End Results (SEER) information plant that US cases of colorectal cancer inward persons aged forty-49 years have got increased significantly since 1995, with the greatest average annual percentage increase for distant cancers, at 2.nine%, while localized together with regional illness each increased < 1.5% per yr. Inimprover, the proportion of distant colorectal cancers in this historic period grouping increased significantly from 1990-1994 to 2011–2015, from 22% to 27%, patch the proportion of localized cases did non modify, and the proportion of regional cases decreased. These authors point out that these results point a true increment inward chance, because if the increase had reflected before detection due to wider exercise of colonoscopy, before stage at diagnosis would live expected.[31]

eMedicine Logo


The approximate 5-twelvemonth survival rate for colorectal cancer patients inwards the U.S. (all stages included) is 64.6%. [23] Survival is inversely related to stage: approximate5-yr relative survival rates are every bit follows:

  • Localized illness: 90.2%
  • Regional illness: 71.8%
  • Distant illness: 14.3%

A study by Chua et al plant that just about 1 in every iii patients who undergo resection for colorectal liver metastases get actual 5-year survivors. [32] Of those, about half live 10 years too are cured of colorectal livermetastases. A multivariate analysis of 1001 patients who underwent potentially curative resection of liver metastases identified 5 factors equally independent predictors of worse outcome [33] :

  • Size greater than 5 cm
  • Disease-gratis interval of less than a year
  • More than one tumor
  • Primary lymph-node positivity
  • Carcinoembryonic antigen (CEA) levelgreater than 200 ng/mL

Aggarwal et al establish that circulating tumor cells measured at baseline afterward the initiation of new therapy inwards patients with metastatic colorectal cancer independently predicted survival; inward patients with a baseline carcinoembryonic antigen (CEA) value of 25 ng/mL or higher, those with low baseline levels of circulating tumor cells (< 3) had longer survival. Both the number of circulating tumor cells in addition to the CEA level measured at 6-12 weeks independentlypredicted survival. [34]

Research suggests a role for intra-tumoral immune reply equally a predictor of clinical outcome in patients with colorectal cancer, in addition to more traditional pathological in addition to molecular markers. Katz et al reported that inwards patients with colorectal liver metastases, high numbers of T regulatory cells relative to CD4 or CD8 T cells predicted pitiful outcome[35]

A study by Yothers et al found that dark patients with resected stage II and stage III colon cancer had worse overall and recurrence-gratuitous survival compared with white patients who underwent the same therapy. Five-yr overall survival rate was 68.2% for blacks and 72.8% for whites; the three-year recurrence-gratuitous survival was 68.4% inwards blacks and 72.1% inwards whites.[36]

A study by Campbell et al found that prediagnosis trunk volume index (BMI) is an important predictor of survival amid patients with nonmetastatic colorectal cancer, whereas postdiagnosis BMI is non. [37] A split study from Campbell et al constitute that spending 6 or more hours per twenty-four hour period sitting was associated with higher all-cause mortality compared withsitting less than 3 hours per solar day. The study concluded that increased recreational physical activity in patients with colorectal carcinoma reduces mortality. [38]

Morikawa et al reported that inward patients with colorectal cancer that tested negative for cadherin-associated poly peptide β 1 (CTNNB1 or β-catenin), high physical activity (≥xviii metabolic equivalent job [MET] hours/week) afterwards diagnosis was associated withsignificantly amend cancer-specific survival. No association betwixt physical activity in addition to survival was seen in CTNNB1–positive cases. [39]

A review of viii trials past Rothwell et al plant that resource allotment to aspirin reduced expiry caused by cancer. Benefit was apparent later 5 years of follow-upward. The 20-year gamble of cancer decease was as well lower inward the aspirin grouping for all solid cancers. A latent period of 5 years wasobserved before take a chance of death was decreased for esophageal, pancreatic, encephalon, and lung cancers. A more than delayed latent period was observed for breadbasket, colorectal, and prostate cancer. The overall event on 20-twelvemonth take chances of cancer death was greatest for adenocarcinomas. [twoscore]

A study past Burn et al establish that 600 mg of aspirin per 24-hour interval for a hateful of 25 months reduced cancer incidence later on 55.7 months amidst known carriersof hereditary colorectal cancer. However, farther studies are needed to decide the optimum dose too duration of handling. [41]

Patients with preexisting mental disorders hold an overall higher mortality rate than their counterparts. This higher mortality rate tin can be attributed to a lack of surgical procedure, chemotherapy, in addition to radiation therapy, especially inwards patients with psychotic disorders too dementia. Improved publichealth initiatives are needed to improve colon cancer detection as well as handling inward older adults with mental disorders. [42]

A study past Phipps et al plant that smoking is besides associated with increased mortality after colorectal cancer diagnosis, especially inward patients whose cancer has high microsatellite instability. [43] A study by Dehal et al foundthat patients with colorectal cancer too type 2 diabetes mellitus have got a higher adventure of mortality than those without, most notably a higher run a risk due to cardiovascular illness. [44]

eMedicine Logo

  1. PDQ Adult Treatment Editorial Board.Colon Cancer Treatment–Health Professional Version. National Cancer Institute. Available at Jan 20, 2023; Accessed: Jan 25, 2023.
  2. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, as well as oxaliplatin combinations inwardspatients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004 Jan 1. 22(1):23-thirty. [QxMD MEDLINE Link].
  3. Haller DG, Catalano PJ, Macdonald JS, O’Rourke MA, Frontiera MS, Jackson DV. Phase III study of fluorouracil, leucovorin, as well as levamisole inward high-take a chance stage II in addition to III colon cancer: terminal study of Intergroup 0089. J Clin Oncol. 2005 Dec 1.23(34):8671-8. [QxMD MEDLINE Link].
  4. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, as well as leucovorin for metastatic colorectal cancer. due north Engl J Med. 2004 Jun 3. 350(23):2335-42. [QxMD MEDLINE Link].
  5. Sanoff HK, Sargent DJ,Campbell ME, et al. Five-twelvemonth information and prognostic constituent analysis of oxaliplatin too irinotecan combinations for advanced colorectal cancer: N9741. J Clin Oncol. 2008 Dec 10. 26(35):5721-7. [QxMD MEDLINE Link].
  6. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger air-conditioning, Leppert M, et al. Genetic alterations during colorectal-tumor evolution. northward Engl J Med. 1988Sep 1. 319(9):525-32. [QxMD MEDLINE Link].
  7. Chang WH, Cerione RA, Antonyak MA. Extracellular Vesicles in addition to Their Roles inwards Cancer Progression. Methods Mol Biol. 2021. 2174:143-170. [QxMD MEDLINE Link]. [Full Text].
  8. Zhao X, Yuan C, Wangmo D, Subramanian S. Tumor secreted extracellular vesicles regulate T-cell costimulation and tin be manipulated to stimulate tumor specific T-prison cell responses. Gastroenterology. 2021 Apr 22. [QxMD MEDLINE Link].
  9. Burn J, Bishop DT, Mecklin JP, Macrae F, et al. Effect of aspirin or resistant starch on colorectal neoplasia inward theLynch syndrome. northward Engl J Med. 2008 Dec eleven. 359(24):2567-78. [QxMD MEDLINE Link].
  10. Meyerhardt JA, Niedzwiecki D, Hollis D, et al. Association of dietary patterns with cancer recurrence as well as survival in patients with stage III colon cancer. JAMA. 2007 Aug xv. 298(7):754-64. [QxMD MEDLINE Link].
  11. Aune D, Chan DS, Lau R, et al. Dietary fibre, whole grains, together with gamble of colorectal cancer: systematic review too dose-response meta-analysis of prospective studies. BMJ. 2011 Nov 10. 343:d6617. [QxMD MEDLINE Link]. [Full Text].
  12. Pala V, Sieri S, Berrino F, etal. Yogurt consumption and take a chance of colorectal cancer in the Italian European prospective investigation into cancer in addition to nutrition cohort. Int J Cancer. 2011 Dec 1. 129(xi):2712-9. [QxMD MEDLINE Link].
  13. Tabung FK, Liu L, Wang W, Fung TT, Wu K, Smith-Warner SA, et al. Association of Dietary Inflammatory Potential With Colorectal Cancer Risk inwards Men together with Women. JAMA Oncol.2018 Jan 18. [QxMD MEDLINE Link].
  14. Tsoi KK, Pau CY, Wu WK, Chan FK, Griffiths S, Sung JJ. Cigarette smoking together with the chance of colorectal cancer: a meta-analysis of prospective cohort studies. Clin Gastroenterol Hepatol. 2009 Jun. 7(6):682-688.e1-5. [QxMD MEDLINE Link].
  15. Cho E, Lee JE, Rimm EB, Fuchs CS, Giovannucci EL. Alcohol consumption too the take a chance of colon cancer past family unit history of colorectal cancer. Am J Clin Nutr. 2012 Feb. 95(2):413-9. [QxMD MEDLINE Link]. [Full Text].
  16. Yuhara H, Steinmaus C, Cohen SE, Corley DA, TeiY, Buffler PA. Is diabetes mellitus an independent hazard ingredient for colon cancer as well as rectal cancer?. Am J Gastroenterol. 2011 Nov. 106(xi):1911-21; quiz 1922. [QxMD MEDLINE Link].
  17. Jacobs ET, Ahnen DJ, Ashbeck EL, Baron JA, Greenberg ER, Lance P, et al. Association betwixt trunk mass index in addition to colorectal neoplasia at follow-upwardly colonoscopy: a pooling study. Am JEpidemiol. 2009 Mar xv. 169(6):657-66. [QxMD MEDLINE Link].
  18. Bailly L, Fabre R, Pradier C, Iannelli A. Colorectal Cancer Risk Following Bariatric Surgery in a Nationwide Study of French Individuals With Obesity. JAMA Surg. 2020 Mar xi. [QxMD MEDLINE Link].
  19. MorikawaT, Kuchiba A, Lochhead P, et al. Prospective Analysis of Body Mass Index, Physical Activity, in addition to Colorectal Cancer Risk Associated with ß-Catenin (CTNNB1) Status. Cancer Res. 2013 Mar 1. 73(5):1600-10. [QxMD MEDLINE Link]. [Full Text].
  20. Zhou E, Wang L, Santiago CN, Nanavati J, Rifkin S, Spence E,et al. Adult-Attained Height as well as Colorectal Cancer Risk: A Cohort Study, Systematic Review in addition to Meta-Analysis. Cancer Epidemiol Biomarkers Prev. 2022 Mar 1. [QxMD MEDLINE Link].[Full Text].
  21. Goncalves MD, Lu C, Tutnauer J, Hartman TE, Hwang SK, Murphy CJ, et al. High-fructose corn syrup enhances intestinal tumor growth in mice.Science. 2019 Mar 22. 363 (6433):1345-1349. [QxMD MEDLINE Link].
  22. Zhang J, Haines C, Watson AJM, Hart AR, Platt MJ, Pardoll DM, et al. Oral antibiotic exercise too hazard of colorectal cancer inward the UK, 1989-2012: a matched example-command study. Gut. 2019 Aug xix. [QxMD MEDLINE Link].
  23. Surveillance, Epidemiology, together with End Results Program. Cancer Stat Facts: Colorectal Cancer. National Cancer Institute. Available at Accessed: Jan 25, 2023.
  24. Cancer Facts & Figures 2023. American Cancer Society. Available at with-statistics/annual-cancer-facts-too-figures/2023/2023-cancer-facts-and-figures.pdf. Accessed: Jan 25, 2023.
  25. Siegel RL, Fedewa SA, Anderson WF, Miller KD, Ma J, Rosenberg PS, et al. ColorectalCancer Incidence Patterns inwards the USA, 1974–2013. J Natl Cancer Inst. 28 Feb 2017. 109:[Full Text].
  26. Kahi CJ, Pohl H, Myers LJ, Mobarek D, Robertson DJ, Imperiale TF. Colonoscopy as well as Colorectal Cancer Mortality inward the Veterans Affairs Health Care System: A Case-Control Study. AnnIntern Med. 2018 Mar xiii. [QxMD MEDLINE Link].
  27. World Health Organization, International Agency for Research on Cancer. Colorectal Cancer. Available at Accessed: Jan 25, 2023.
  28. Malvezzi M, Carioli G, Bertuccio P, Boffetta P, Levi F, La Vecchia C, et al. European cancer mortality predictions for the twelvemonth 2018 with focus on colorectal cancer. Ann Oncol. 2018 Mar 19. [QxMD MEDLINE Link]. [Full Text].
  29. GiaquintoAN, Miller KD, Tossas KY, Winn RA, Jemal A, Siegel RL. Cancer statistics for African American/Black People 2022. CA Cancer J Clin. 2022 May. 72 (3):202-229. [QxMD MEDLINE Link]. [Full Text].
  30. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, Anderson JC, et al.Colorectal cancer statistics, 2020. CA Cancer J Clin. 2020 Mar 5. [QxMD MEDLINE Link]. [Full Text].
  31. Meester RGS, Mannalithara A, Lansdorp-Vogelaar I, Ladabaum U. Trends inwards Incidence too Stage at Diagnosis of Colorectal Cancer inwards Adults Aged xl Through 49 Years, 1975-2015.JAMA. 2019 May 21. 321 (nineteen):1933-1934. [QxMD MEDLINE Link].
  32. Chua TC, Saxena A, Chu F, Zhao J, Morris DL. Predictors of cure subsequently hepatic resection of colorectal liver metastases: an analysis of actual 5- and 10-year survivors. J Surg Oncol. 2011 Jun. 103(8):796-800. [QxMD MEDLINE Link].
  33. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence subsequently hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg. 1999 Sep. 230(3):309-18; word 318-21. [QxMD MEDLINE Link].
  34. Aggarwal C, Meropol NJ, Punt CJ, Iannotti north, Saidman BH, Sabbath KD, et al.Relationship amid circulating tumor cells, CEA and overall survival inwards patients with metastatic colorectal cancer. Ann Oncol. 2012 Oct 1. [QxMD MEDLINE Link].
  35. Katz SC, Bamboat ZM, Maker AV, Shia J, Pillarisetty VG, Yopp air conditioning, et al. Regulatory T Cell Infiltration Predicts Outcome Following Resection of Colorectal Cancer Liver Metastases. Ann Surg Oncol. 2012 Sep 26.[QxMD MEDLINE Link].
  36. Yothers G, Sargent DJ, Wolmark north, et al. Outcomes Among Black Patients With Stage II in addition to III Colon Cancer Receiving Chemotherapy: An Analysis of ACCENT Adjuvant Trials. J Natl Cancer Inst. 2011 Oct xix. 103(20):1498-1506. [QxMD MEDLINE Link].[Full Text].
  37. Campbell PT, Newton CC, Dehal AN, et al. Impact of body volume index on survival later colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012 Jan 1. xxx(1):42-52. [QxMD MEDLINE Link].
  38. CampbellPT, Patel AV, Newton CC, Jacobs EJ, Gapstur SM. Associations of recreational physical activity as well as leisure time spent sitting with colorectal cancer survival. J Clin Oncol. 2013 Mar 1. 31(7):876-85. [QxMD MEDLINE Link].
  39. Morikawa T, Kuchiba A, Yamauchi M, et al. Association of CTNNB1 (beta-catenin) alterations, body volume index, as well as physical activity with survival inward patientswith colorectal cancer. JAMA. 2011 Apr 27. 305(xvi):1685-94. [QxMD MEDLINE Link]. [Full Text].
  40. Rothwell PM, Fowkes GR, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term run a risk of decease due to cancer: analysis of private patient data from randomized trials.Lancet. Dec 7/2010; Early online publication. [Full Text].
  41. Burn J, Gerdes AM, Macrae F, et al. Long-term consequence of aspirin on cancer take chances in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet. 2011 Dec 17. 378(9809):2081-7.[QxMD MEDLINE Link]. [Full Text].
  42. Baillargeon J, Kuo YF, Lin YL, et al. Effect of mental disorders on diagnosis, handling, too survival of older adults with colon cancer. J Am Geriatr Soc. 2011 Jul. 59(7):1268-73. [QxMD MEDLINELink].
  43. Phipps AI, Baron J, Newcomb PA. Prediagnostic smoking history, alcohol consumption, in addition to colorectal cancer survival: The Seattle Colon Cancer Family Registry. Cancer. 2011 Nov 1. 117(21):4948-57. [QxMD MEDLINE Link]. [Full Text].
  44. DehalAN, Newton CC, Jacobs EJ, et al. Impact of diabetes mellitus too insulin usage on survival afterward colorectal cancer diagnosis: the Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol. 2012 Jan 1. xxx(1):53-ix. [QxMD MEDLINE Link].
  45. Arhi CS, Ziprin P, Bottle A, Burns EM, Aylin P, Darzi A. Colorectal cancer patients nether the age of 50 experience delays inwards primary tending leadingto emergency diagnoses: a population-based study. Colorectal Dis. 2019 Aug 6. [QxMD MEDLINE Link]. [Full Text].
  46. [Guideline] Shaukat A, Kahi CJ, Burke CA, Rabeneck L, Sauer BG, Rex DK. ACG Clinical Guidelines: Colorectal Cancer Screening 2021. Am J Gastroenterol. 2021 Mar 1. 116(3):458-479. [QxMD MEDLINE Link]. [Full Text].
  47. Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J, et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) too microsatellite instability. JNatl Cancer Inst. 2004 Feb eighteen. 96(4):261-8. [QxMD MEDLINE Link]. [Full Text].
  48. Thirunavukarasu P, Sukumar S, Sathaiah M, Mahan M, Pragatheeshwar KD, Pingpank JF, et al. C-stage inwards Colon Cancer: Implications of Carcinoembryonic Antigen Biomarker inward Staging, Prognosis, together with Management. J Natl CancerInst. 2011 Apr 20. 103(8):689-97. [QxMD MEDLINE Link].
  49. When Should You Start Getting Screened for Colorectal Cancer?. American Cancer Society. Available at February 4, 2021; Accessed: January 25, 2023.
  50. Littlejohn C, Hilton S, Macfarlane GJ, Phull P. Systematic review and meta-analysis of the evidence for flexiblesigmoidoscopy equally a screening method for the prevention of colorectal cancer. Br J Surg. 2012 Sep 21. [QxMD MEDLINE Link].
  51. Holme O, et al for the NORCCAP Study Group. Long-Term Effectiveness of Sigmoidoscopy Screening on Colorectal Cancer Incidence together with Mortality inward Women and Men: A Randomized Trial. Ann Intern Med. 24 Apr 2018.[Full Text].
  52. Wilschut JA, Habbema JD, van Leerdam ME, et al. Fecal occult blood testing when colonoscopy capacity is express. J Natl Cancer Inst. 2011 Dec 7. 103(23):1741-51. [QxMD MEDLINE Link].
  53. Jensen CD, Corley DA, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Fecal Immunochemical Test Program Performance Over 4 Rounds of Annual Screening: A Retrospective Cohort Study. Ann Intern Med. 2016 Jan 26. [QxMD MEDLINE Link]. [Full Text].
  54. Corley DA, JensenCD, Quinn VP, Doubeni CA, Zauber AG, Lee JK, et al. Association Between Time to Colonoscopy After a Positive Fecal Test Result in addition to Risk of Colorectal Cancer and Cancer Stage at Diagnosis. JAMA. 2017 Apr 25. 317 (sixteen):1631-1641. [QxMD MEDLINE Link].
  55. Gandhi S, Narula N, Mosleh W, Marshall JK, Farkouh M. Meta-analysis: colonoscopic mail-polypectomy bleeding inward patients oncontinued clopidogrel therapy. Aliment Pharmacol Ther. 2013 May. 37(10):947-52. [QxMD MEDLINE Link].
  56. Nelson R. FDA Approves Cologuard for Colorectal Cancer Screening. Medscape Medical News. Available at August 11, 2014; Accessed: Jan 30, 2018.
  57. Brooks M. FDA Clears First Blood-Based Colorectal Cancer Screening Test. Medscape Medical News. Available at Apr xiv, 2016; Accessed: January 30, 2018.
  58. [Guideline] Levin B, Lieberman DA, McFarland B, et al. Screening as well as surveillance for the early on detection of colorectal cancer tooadenomatous polyps, 2008: a articulation guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008 May-Jun. 58(3):130-lx. [QxMD MEDLINE Link].
  59. Karsenti D, Tharsis G, Burtin P, Venezia F, Tordjman G, Gillet A, et al. Adenoma too advanced neoplasia detection rates increment from 45years of age. World J Gastroenterol. 2019 Jan 28. 25 (4):447-456. [QxMD MEDLINE Link]. [Full Text].
  60. Lasser KE, Murillo J, Lisboa S, et al. Colorectal cancer screening amongst ethnically various, depression-income patients: a randomized controlled trial. Arch Intern Med. 2011 May 23.171(10):906-12. [QxMD MEDLINE Link].
  61. [Guideline] Johnson DA, Barkun AN, Cohen LB, Dominitz JA, Kaltenbach T, Martel M, et al. Optimizing adequacy of bowel cleansing for colonoscopy: recommendations from the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2014 Oct. 109 (10):1528-45. [QxMD MEDLINELink]. [Full Text].
  62. Given Imaging Receives FDA Clearance for PillCam® COLON in Patients Following Incomplete Colonoscopy. Med Device Online. Available at February 3, 2014; Accessed: January 25, 2023.
  63. Spada C, De Vincentis F, Cesaro P, Hassan C, Riccioni ME, Minelli Grazioli L, et al. Accuracy as well as security of minute-generation PillCam COLON capsule for colorectal polyp detection.Therap Adv Gastroenterol. 2012 May. 5(3):173-8. [QxMD MEDLINE Link]. [Full Text].
  64. [Guideline] Gupta S, Lieberman D, Anderson JC, Burke CA, Dominitz JA, Kaltenbach T, et al. Recommendations for Follow-Up After Colonoscopy in addition to Polypectomy: A Consensus Update by the US Multi-Society Task Force onColorectal Cancer. Gastroenterology. 2020 Feb 5. 143(3):844-57. [QxMD MEDLINE Link].
  65. [Guideline] Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK, et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology,in addition to the American Society of Clinical Oncology. J Clin Oncol. 2017 May 1. 35 (13):1453-1486. [QxMD MEDLINE Link]. [Full Text].
  66. American Joint Committee on Cancer. Colon together with Rectum. Amin MB, Edge S, Greene F, Byrd DR, Brookland RK, et al, eds. AJCC Cancer staging manual. 8th ed. NewYork: Springer; 2017.
  67. Ogino S, Kawasaki T, Kirkner GJ, Ohnishi M, Fuchs CS. 18q loss of heterozygosity in microsatellite stable colorectal cancer is correlated with CpG island methylator phenotype-negative (CIMP-0) too inversely with CIMP-depression as well as CIMP-high. BMC Cancer. 2007 May 2. 7:72. [QxMD MEDLINE Link].
  68. Jimeno A,Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS Mutations together with Sensitivity to Epidermal Growth Factor Receptor Inhibitors inward Colorectal Cancer: Practical Application of Patient Selection. J Clin Oncol. 2009 Jan 5. [QxMD MEDLINE Link].
  69. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair every bit a predictive mark forlack of efficacy of fluorouracil-based adjuvant therapy inward colon cancer. J Clin Oncol. 2010 Jul 10. 28 (20):3219-26. [QxMD MEDLINE Link]. [Full Text].
  70. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status equally a predictor of do good from fluorouracil-based adjuvantchemotherapy for colon cancer. north Engl J Med. 2003 Jul 17. 349(3):247-57. [QxMD MEDLINE Link].
  71. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the land of the local immune reaction. J Clin Oncol. 2011 Feb 20. 29(6):610-8.[QxMD MEDLINE Link].
  72. Le Voyer TE, Sigurdson ER, Hanlon AL, et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol. 2003 Aug 1. 21(xv):2912-9. [QxMD MEDLINE Link].
  73. GundersonLL, Jessup JM, Sargent DJ, Greene FL, Stewart AK. Revised TN categorization for colon cancer based on national survival outcomes data. J Clin Oncol. 2010 Jan 10. 28(2):264-71. [QxMD MEDLINE Link]. [Full Text].
  74. Hugen northward, van de Velde CJ, de Wilt JH, Nagtegaal ID. Metastatic design inward colorectalcancer is strongly influenced by histological subtype. Ann Oncol. 2014 Mar. 25(3):651-7. [QxMD MEDLINE Link].
  75. Boggs W. Histology influences colorectal cancer metastatic blueprint. Reuters Health Information. March eleven, 2014. [Full Text].
  76. [Guideline]Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2021 Dec 22. 22(sixteen):JCO2102538. [QxMD MEDLINE Link]. [Full Text].
  77. Boller AM, Nelson H. Colon together with rectal cancer: laparoscopic or open?. ClinCancer Res. 2007 Nov fifteen. 13(22 Pt 2):6894s-6s. [QxMD MEDLINE Link].
  78. Fleshman J, Sargent DJ, Green E, Anvari M, Stryker SJ, Beart RW Jr. Laparoscopic colectomy for cancer is non inferior to open surgical procedure based on 5-twelvemonth data from the COST Study Group trial. Ann Surg. 2007 Oct. 246(4):655-62; discussion 662-4. [QxMDMEDLINE Link].
  79. Jayne DG, Guillou PJ, Thorpe H, et al. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-yr results of the UK MRC CLASICC Trial Group. J Clin Oncol. 2007 Jul 20. 25(21):3061-8. [QxMD MEDLINE Link].
  80. Kuhry E, Schwenk WF, Gaupset R, Romild U, Bonjer HJ. Long-term results oflaparoscopic colorectal cancer resection. Cochrane Database Syst Rev. 2008 Apr sixteen. CD003432. [QxMD MEDLINE Link].
  81. Lacy AM, Delgado S, Castells A, et al. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open surgical process for colon cancer. Ann Surg. 2008 Jul. 248(1):1-7. [QxMDMEDLINE Link].
  82. Veldkamp R, Kuhry E, Hop WC, et al. Laparoscopic surgical operation versus open up operation for colon cancer: short-term outcomes of a randomised trial. Lancet Oncol. 2005 Jul. 6(7):477-84. [QxMD MEDLINE Link].
  83. Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG. Outcome of Primary Tumor inwards Patients WithSynchronous Stage IV Colorectal Cancer Receiving Combination Chemotherapy Without Surgery As Initial Treatment. J Clin Oncol. 2009 Jun 1. [QxMD MEDLINE Link].
  84. Nitzkorski JR, Farma JM, Watson JC, Siripurapu V, Zhu F, Matteotti RS, et al. Outcome together with natural history of patients with stage IV colorectal cancer receiving chemotherapy without primary tumor resection. Ann SurgOncol. 2012 Feb. xix(2):379-83. [QxMD MEDLINE Link].
  85. Venderbosch S, de Wilt JH, Teerenstra S, et al. Prognostic value of resection of primary tumor inwards patients with stage IV colorectal cancer: retrospective analysis of two randomized studies together with a review of the literature. Ann Surg Oncol. 2011 Nov. eighteen(12):3252-sixty.[QxMD MEDLINE Link]. [Full Text].
  86. Di Benedetto F, Berretta M, D’Amico G, et al. Liver resection for colorectal metastases inwards older adults: a paired matched analysis. J Am Geriatr Soc. 2011 Dec. 59(12):2282-ninety. [QxMD MEDLINE Link].
  87. Brouquet A, Overman MJ, Kopetz S, et al. Is resection of colorectal liver metastases subsequently a second-line chemotherapy regimen justified?. Cancer. 2011 Oct 1. 117(xix):4484-92. [QxMD MEDLINE Link]. [Full Text].
  88. House MG, Kemeny NE, Gonen M, et al.Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy subsequently hepatic resection for metastatic colorectal cancer. Ann Surg. 2011 Dec. 254(6):851-6. [QxMD MEDLINE Link].
  89. van Hooft JE, Bemelman WA, Oldenburg B, et al. Colonic stenting versus emergency surgical operation for sharp left-sided malignant colonic obstacle: a multicentrerandomised trial. Lancet Oncol. 2011 Apr. 12(4):344-52. [QxMD MEDLINE Link].
  90. Sargent D, Sobrero A, Grothey A, O’Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy inwards colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009 Feb 20. 27(6):872-7.[QxMD MEDLINE Link].
  91. Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5-fluorouracil/folinic acid equally adjuvant therapy for stage III colon cancer: terminal results from the X-ACT trial with analysis by age too preliminary evidence of a pharmacodynamic mark of efficacy. Ann Oncol. 2012 May. 23 (5):1190-1197.[QxMD MEDLINE Link]. [Full Text].
  92. Schmoll HJ, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase IIITrial. J Clin Oncol. 2015 Nov 10. 33 (32):3733-40. [QxMD MEDLINE Link]. [Full Text].
  93. van Erning FN, Creemers GJ, De Hingh IH, Loosveld OJ, Goey SH, Lemmens VE. Reduced take chances of distant recurrence subsequently adjuvant chemotherapyinward patients with stage III colon cancer aged 75 years or older. Ann Oncol. 2013 Aug 8. [QxMD MEDLINE Link].
  94. André T, Iveson T, Labianca R, Meyerhardt JA, Souglakos I, Yoshino T, et al. The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX(FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design too Current Status. Curr Colorectal Cancer Rep. 2013. nine:261-269. [QxMD MEDLINE Link]. [Full Text].
  95. Lieu C, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al.Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol. 2019 Jun 1. 37 (xvi):1436-1447. [QxMD MEDLINE Link]. [Full Text].
  96. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: ColonCancer. Available at Version 2.2022 — October 27, 2022; Accessed: January 25, 2023.
  97. Quasar Collaborative Group, Gray R, Barnwell J, et al. Adjuvant chemotherapy versus observation inward patients with colorectal cancer: a randomised study. Lancet. 2007 Dec 15. 370(9604):2020-nine.[QxMD MEDLINE Link].
  98. O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011 Sep 1. 29(25):3381-8. [QxMD MEDLINE Link]. [Full Text].
  99. Petrelli F, Labianca R, Zaniboni A, et al. Assessment of Duration too Effects of 3 vs 6 Months of Adjuvant Chemotherapy inward High-Risk Stage II Colorectal Cancer: A Subgroup Analysis of the TOSCA Randomized Clinical Trial. JAMA Oncol. 2020 Feb thirteen. [QxMD MEDLINE Link].
  100. Kim GP, Sargent DJ, Mahoney MR, Rowland KM Jr, Philip PA, Mitchell E,et al. Phase III noninferiority trial comparing irinotecan with oxaliplatin, fluorouracil, together with leucovorin inwards patients with advanced colorectal carcinoma previously treated with fluorouracil: N9841. J Clin Oncol. 2009 Jun 10. 27(17):2848-54. [QxMD MEDLINE Link]. [Full Text].
  101. Seymour MT, ThompsonLC, Wasan HS, et al. Chemotherapy options inward elderly together with fragile patients with metastatic colorectal cancer (MRC FOCUS2): an open up-label, randomised factorial trial. Lancet. 2011 May 21. 377(9779):1749-59. [QxMD MEDLINE Link].
  102. Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma due north, et al. Randomized trial of TAS-102 for refractory metastatic colorectalcancer. due north Engl J Med. 2015 May 14. 372 (20):1909-xix. [QxMD MEDLINE Link].
  103. Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 2004. 20 (4-5):199-206. [QxMD MEDLINE Link]. [FullText].
  104. Bennouna J, Sastre J, Arnold D, Osterlund P, Greil R, Van Cutsem E, et al. Continuation of bevacizumab subsequently kickoff progression in metastatic colorectal cancer (ML18147): a randomised stage 3 trial. Lancet Oncol. 2013 Jan. 14(1):29-37. [QxMD MEDLINE Link].
  105. Kabbinavar FF, Hurwitz HI, Yi J, Sarkar S, Rosen O. Additionof bevacizumab to fluorouracil-based kickoff-line treatment of metastatic colorectal cancer: pooled analysis of cohorts of older patients from 2 randomized clinical trials. J Clin Oncol. 2009 Jan 10. 27(2):199-205. [QxMD MEDLINE Link].
  106. Goey KKH, Elias SG, van Tinteren H, Laclé MM, Willems SM, Offerhaus GJA, et al. Maintenance handling with capecitabine too bevacizumab versusobservation inwards metastatic colorectal cancer: updated results together with molecular subgroup analyses of the stage 3 CAIRO3 study. Ann Oncol. 2017 Sep 1. 28 (nine):2128-2134. [QxMD MEDLINE Link]. [Full Text].
  107. Tebbutt NC, Murphy F, Zannino D, et al. Risk of arterial thromboembolic events inpatients with advanced colorectal cancer receiving bevacizumab. Ann Oncol. 2011 Aug. 22(8):1834-8. [QxMD MEDLINE Link].
  108. Allegra CJ, Yothers G, O’Connell MJ, Sharif S, Petrelli NJ, Colangelo LH, et al. Phase III trial assessing bevacizumab inwards stages II too III carcinoma of the colon: results of NSABP protocol C-08. J Clin Oncol. 2011 Jan 1. 29(1):eleven-6.[QxMD MEDLINE Link].
  109. Stark, Angela. FDA approves showtime biosimilar for the treatment of cancer. FDA News Release. 09/fourteen/2017. Available at
  110. Cunningham D,Humblet Y, Siena S, et al. Cetuximab monotherapy in addition to cetuximab plus irinotecan inwards irinotecan-refractory metastatic colorectal cancer. due north Engl J Med. 2004 Jul 22. 351(4):337-45. [QxMD MEDLINE Link].
  111. Van Cutsem E, Köhne CH, Láng I, Folprecht G, Nowacki MP, Cascinu S, et al. Cetuximab plus irinotecan, fluorouracil, too leucovorin as commencement-line treatment for metastatic colorectalcancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011 May 20. 29(xv):2011-ix. [QxMD MEDLINE Link].
  112. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab in addition to chemotherapy equally initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2. 360(14):1408-17.[QxMD MEDLINE Link]. [Full Text].
  113. Lin AY, Buckley NS, Lu AT, et al. Effect of KRAS mutational status in advanced colorectal cancer on the outcomes of anti-epidermal growth constituent receptor monoclonal antibody therapy: a systematic review in addition to meta-analysis. Clin Colorectal Cancer. 2011 Mar 1.10(1):63-ix. [QxMD MEDLINE Link].
  114. Chustecka Z. FDA Approves Panitumumab for Use With FOLFOX inward mCRC. Medscape Medical News. Available at Accessed: June 2, 2014.
  115. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R,Barugel M, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 solitary every bit showtime-line handling inwards patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010 Nov 1. 28(31):4697-705. [QxMD MEDLINE Link].
  116. Peeters M, Price TJ, Cervantes A, Sobrero AF, DucreuxM, Hotko Y, et al. Randomized stage III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI lonely equally second-line treatment inwards patients with metastatic colorectal cancer. J Clin Oncol. 2010 Nov 1. 28(31):4706-13. [QxMD MEDLINE Link].
  117. Price TJ, Peeters M, Kim TW, Li J, Cascinu S, Ruff P, et al. Panitumumab versus cetuximab inwardspatients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open up-label, non-inferiority phase 3 study. Lancet Oncol. 2014 May. xv(6):569-79. [QxMD MEDLINE Link].
  118. Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, in addition topanitumumab compared with chemotherapy together with bevacizumab solitary for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10. 27(5):672-eighty. [QxMD MEDLINE Link].
  119. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, et al. Fluorouracil, leucovorin, too oxaliplatin with in addition to without cetuximab in the get-go-line handling of metastatic colorectal cancer. JClin Oncol. 2009 Feb 10. 27(5):663-71. [QxMD MEDLINE Link].
  120. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, et al. Panitumumab-FOLFOX4 treatment together with RAS mutations inward colorectal cancer. N Engl J Med. 2013 Sep 12. 369(11):1023-34. [QxMD MEDLINE Link].
  121. Kim TW, Elme A, Kusic Z, Park JO, Udrea AA, Kim SY, et al. A phase 3 trial evaluating panitumumab plus best supportive attention vs best supportive aid inwards chemorefractory wild-type KRAS or RAS metastatic colorectal cancer. Br J Cancer. 2016 Nov 8. 115 (10):1206-1214. [QxMD MEDLINE Link]. [Full Text].
  122. Tabernero J, Yoshino T, Cohn AL, Obermannova R, Bodoky G, Garcia-Carbonero R, et al. Ramucirumab versus placebo inward combination with second-line FOLFIRI inwards patients with metastatic colorectal carcinoma that progressed during or afterwards offset-line therapy with bevacizumab, oxaliplatin, as well as a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, stage 3 study. Lancet Oncol. 2015 Apr 10.[QxMD MEDLINE Link].
  123. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab inward patients with metastatic deoxyribonucleic acid mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open up-label, multicentre, phase 2 study. Lancet Oncol. 2017 Jul nineteen. [QxMD MEDLINELink]. [Full Text].
  124. Overman MJ, Lonardi S, Wong KYM, Lenz HJ, Gelsomino F, Aglietta M, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab inwards DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018 Mar 10. 36 (8):773-779.[QxMD MEDLINE Link].
  125. Opdivo (nivolumab) [bundle insert]. Bristol-Myers Squibb Company: Princeton, NJ 08543 USA. 7/2017. Available at [Full Text].
  126. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, et al. PD-1 Blockade inwards Tumors with Mismatch-RepairDeficiency. north Engl J Med. 2015 Jun 25. 372 (26):2509-20. [QxMD MEDLINE Link]. [Full Text].
  127. Stivarga (regorafenib) [packet insert]. Wayne, NJ: Bayer HealthCare Pharmaceuticals Inc. September 2012. Available at[Full Text].
  128. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013 Jan 26. 381 (9863):303-12.[QxMD MEDLINE Link].
  129. Patel A, Dominicus W. Ziv-aflibercept inward metastatic colorectal cancer. Biologics. 2014. 8:13-25. [QxMD MEDLINE Link]. [Full Text].
  130. Van Cutsem E, et al. Aflibercept PlusFOLFIRI vs. Placebo Plus FOLFIRI inward Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol. 2016 Jun. eleven (3):383-400. [QxMD MEDLINE Link].[Full Text].
  131. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, too irinotecan improves survival inward a stage III randomized trial inwards patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012 Oct 1.30(28):3499-506. [QxMD MEDLINE Link].
  132. FDA approves an oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor. U.S. Food & Drug Administration. Available at November 26, 2018; Accessed: June 5, 2019.
  133. Kopetz S, Grothey A, Yaeger R, et al. Encorafenib, Binimetinib, and Cetuximab inward BRAFV600E-Mutated Colorectal Cancer. north Engl J Med. 2019 Oct 24. 381 (17):1632-1643. [QxMD MEDLINE Link].
  134. Davenport L. Updated BEACON: Doublet equally Good as Triplet inward Metastatic CRC. Medscape Medical News. Available at June 2, 2020; Accessed: February xi, 2021.
  135. Sartore-Bianchi A, Trusolino L, Martino C, Bencardino K, Lonardi S, et al. Dual-targeted therapy with trastuzumab together with lapatinib inwards treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol. 2016 Apr 20. [QxMD MEDLINE Link].[Full Text].
  136. Otto MA. Tucatinib Plus Trastuzumab Approved for HER2+ Colorectal Cancer. Medscape Medical News. Available at January 20, 2023; Accessed: Jan 240, 2023.
  137. Hendlisz A, Van den Eynde M, Peeters M, Maleux G, Lambert B, Vannoote J, et al. Phase III trial comparing protracted intravenous fluorouracil infusion lonely or with yttrium-ninety resin microspheres radioembolization for liver-express metastatic colorectal cancer refractory to criterion chemotherapy. J Clin Oncol. 2010 Aug 10. 28(23):3687-94. [QxMD MEDLINE Link].
  138. Song M, Wu K, Meyerhardt JA, Ogino S, Wang M, Fuchs CS, et al. Fiber Intake in addition to Survival After Colorectal Cancer Diagnosis. JAMA Oncol. 2017 Nov 2. [QxMD MEDLINE Link]. [Full Text].
  139. Van Blarigan EL, Ou FS, Bainter TM, Fuchs CS, Niedzwiecki D, ZhangS, et al. Associations Between Unprocessed Red Meat in addition to Processed Meat With Risk of Recurrence too Mortality inwards Patients With Stage III Colon Cancer. JAMA Netw Open. 2022 Feb 1. 5 (2):e220145. [QxMD MEDLINE Link]. [Full Text].
  140. [Guideline] Meyerhardt JA, Mangu PB, Flynn PJ, KordeL, Loprinzi CL, Minsky BD, et al. Follow-Up Care, Surveillance Protocol, in addition to Secondary Prevention Measures for Survivors of Colorectal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement. J Clin Oncol. 2013 Nov 12. [QxMD MEDLINE Link].
  141. [Guideline] Labianca R, Nordlinger B, Beretta GD, Mosconi S, Mandalà M, Cervantes A, et al. Early coloncancer: ESMO Clinical Practice Guidelines for diagnosis, handling in addition to follow-upwards. Ann Oncol. 2013 Oct. 24 Suppl 6:vi64-72. [QxMD MEDLINE Link].
  142. Kirkegaard H, Johnsen NF, Christensen J, Frederiksen K, Overvad K, Tjonneland A. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ. 2010 Oct 26.341:c5504. [QxMD MEDLINE Link]. [Full Text].
  143. Kim J, Boushey CJ, Wilkens LR, Haiman CA, Le Marchand L, Park SY. Plant-based dietary patterns defined by a priori indices as well as colorectal cancer run a risk by sexual activity as well as race/ethnicity: the Multiethnic Cohort Study. BMC Med. 2022 Nov 29. 20 (1):430.[QxMD MEDLINE Link]. [Full Text].
  144. Meyerhardt JA, Heseltine D, Niedzwiecki D, Hollis D, Saltz LB, Mayer RJ, et al. Impact of physical activity on cancer recurrence in addition to survival inward patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol. 2006 Aug 1.24(22):3535-41. [QxMD MEDLINE Link].
  145. Baron JA, Barry EL, Mott LA, Rees JR, Sandler RS, et al. A Trial of Calcium and Vitamin D for the Prevention of Colorectal Adenomas. northward Engl J Med. 2015 Oct fifteen. 373 (xvi):1519-30. [QxMD MEDLINE Link].[Full Text].
  146. Barry EL, Peacock JL, Rees JR, Bostick RM, Robertson DJ, Bresalier RS, et al. Vitamin D Receptor Genotype, Vitamin D3 Supplementation, too Risk of Colorectal Adenomas: A Randomized Clinical Trial. JAMA Oncol. 2016 Dec xv. [QxMD MEDLINE Link].
  147. McCullough ML, Zoltick ES, Weinstein SJ, Fedirko V, Wang M, et al. Circulating Vitamin D together with Colorectal Cancer Risk: An International Pooling Project of 17 Cohorts. J Natl Cancer Inst. 2018 Jun fourteen. [QxMD MEDLINE Link].
  148. Arber N, Spicak J, Rácz I, Zavoral M, Breazna A, Gerletti P, et al. Five-twelvemonth analysis of the prevention of colorectalsporadic adenomatous polyps trial. Am J Gastroenterol. 2011 Jun. 106(6):1135-46. [QxMD MEDLINE Link].
  149. Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised as well as observational studies. Lancet. 2007 May 12. 369(9573):1603-thirteen. [QxMD MEDLINELink].
  150. Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009 Feb eighteen. 101(4):256-66. [QxMD MEDLINE Link].
  151. Zhang X, Smith-Warner SA, Chan AT, et al. Aspirin Use, Body Mass Index,Physical Activity, Plasma C-Peptide, together with Colon Cancer Risk inward US Health Professionals. Am J Epidemiol. 2011 Aug xv. 174(4):459-67. [QxMD MEDLINE Link].
  152. Nishihara R, Lochhead P, Kuchiba A, Jung S, Yamauchi M, Liao X, et al. Aspirin exercise in addition to adventure of colorectal cancer according to BRAF mutation status. JAMA. 2013 Jun 26. 309(24):2563-71.[QxMD MEDLINE Link].
  153. Cook NR, Lee IM, Zhang SM, Moorthy MV, Buring JE. Alternate-Day, Low-Dose Aspirin in addition to Cancer Risk: Long-Term Observational Follow-upwards of a Randomized Trial. Ann Intern Med. 2013 Jul xvi. 159(2):77-85. [QxMD MEDLINE Link].
  154. Meyskens FL Jr, McLarenCE, Pelot D, Fujikawa-Brooks S, Carpenter PM, Hawk E, et al. Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial. Cancer Prev Res (Phila Pa). 2008 Jun. 1(1):32-8. [QxMD MEDLINE Link].
  155. [Guideline] American Cancer Society Guideline for Colorectal Cancer Screening. American Cancer Society.Available at May 30, 2018; Accessed: May 25, 2019.
  156. [Guideline] US Preventive Services Task Force., Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, et al. Screening for Colorectal Cancer: US PreventiveServices Task Force Recommendation Statement. JAMA. 2021 May 18. 325 (19):1965-1977. [QxMD MEDLINE Link]. [Full Text].
  157. [Guideline] Qaseem A, Crandall CJ, Mustafa RA, Hicks LA, Wilt TJ, Clinical Guidelines Committee of the American College of Physicians., et al. Screening for ColorectalCancer inward Asymptomatic Average-Risk Adults: A Guidance Statement From the American College of Physicians. Ann Intern Med. 2019 Nov 5. 171 (ix):643-654. [QxMD MEDLINE Link]. [Full Text].
  158. [Guideline] National ComprehensiveCancer Network. NCCN Clinical Practice Guidelines in Oncology: Colorectal Cancer Screening. NCCN. Available at Version 3.2022 — September thirty, 2022; Accessed: January 25, 2023.
  159. [Guideline] National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines inOncology: Genetic/Familial High Risk Assessment: Colorectal. NCCN. Available at Version 2.2022 — Dec 7, 2022; Accessed: January 25, 2023.
  160. [Guideline] Argilés G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO ClinicalPractice Guidelines for diagnosis, handling and follow-upward. Ann Oncol. 2020 Oct. 31 (10):1291-1305. [QxMD MEDLINE Link]. [Full Text].
  161. [Guideline] Stjepanovic north, Moreira L, Carneiro F, Balaguer F, Cervantes A, Balmaña J, et al. Hereditary gastrointestinal cancers: ESMO ClinicalPractice Guidelines for diagnosis, handling in addition to follow-upwardly†. Ann Oncol. 2019 Oct 1. 30 (10):1558-1571. [QxMD MEDLINE Link]. [Full Text].
  162. [Guideline] Rubenstein JH, Enns R, Heidelbaugh J, Barkun A, Clinical Guidelines Committee. American Gastroenterological AssociationInstitute Guideline on the Diagnosis together with Management of Lynch Syndrome. Gastroenterology. 2015 Sep. 149 (3):777-82; quiz e16-7. [QxMD MEDLINE Link]. [Full Text].
  163. [Guideline] Balmaña J, Balaguer F, Cervantes A, Arnold D, ESMO Guidelines Working Group. Familial run a risk-colorectalcancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2013 Oct. 24 Suppl 6:vi73-fourscore. [QxMD MEDLINE Link]. [Full Text].
  164. [Guideline] Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MW, et al. Hereditary colorectal cancer syndromes: American Society ofClinical Oncology Clinical Practice Guideline endorsement of the familial take a chance-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2015 Jan 10. 33 (2):209-17. [QxMD MEDLINE Link]. [Full Text].
  165. [Guideline] Syngal S, Brand RE,Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015 Feb. 110 (2):223-62; quiz 263. [QxMD MEDLINE Link]. [Full Text].
  166. [Guideline] Rutter MD, East J, Rees CJ, Cripps north, Docherty J, Dolwani S, et al. British Society of Gastroenterology/Association of Coloproctology of Great Britain in addition to Ireland/Public Health England post-polypectomy as well as postal service-colorectal cancer resection surveillance guidelines. Gut. 2020 Feb. 69 (2):201-223. [QxMD MEDLINE Link].[Full Text].
  167. Church J, Simmang C, Standards Task Force, American Society of Colon as well as Rectal Surgeons, Collaborative Group of the Americas on Inherited Colorectal Cancer in addition to the Standards Committee of The American Society of Colon as well as Rectal Surgeons. Practice parameters for the handling of patients with dominantly inherited colorectal cancer (familialadenomatous polyposis in addition to hereditary nonpolyposis colorectal cancer). Dis Colon Rectum. 2003 Aug. 46 (8):1001-12. [QxMD MEDLINE Link].
  168. Vogel JD, Felder SI, Bhama AR, Hawkins AT, Langenfeld SJ, Shaffer VO, et al. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer. Dis Colon Rectum. 2022 Feb 1. 65(2):148-177. [QxMD MEDLINE Link]. [Full Text].
  169. [Guideline] Steele SR, Chang GJ, Hendren S, Weiser M, Irani J, Buie WD, et al. Practice Guideline for the Surveillance of Patients After Curative Treatment of Colon too Rectal Cancer. Dis ColonRectum. 2015 Aug. 58 (8):713-25. [QxMD MEDLINE Link]. [Full Text].
  170. [Guideline] Kahi CJ, Boland CR, Dominitz JA, Giardiello FM, Johnson DA, Kaltenbach T, et al. Colonoscopy Surveillance After Colorectal Cancer Resection: Recommendations ofthe US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2016 Mar. 150 (3):758-768.e11. [QxMD MEDLINE Link]. [Full Text].
  171. [Guideline] Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach north, Hantel A, et al. Extended RAS Gene Mutation Testing inward Metastatic ColorectalCarcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol. 2016 Jan 10. 34 (2):179-85. [QxMD MEDLINE Link]. [Full Text].
  172. [Guideline] Van CutsemE, Cervantes A, Adam R, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016 Aug. 27 (8):1386-422. [QxMD MEDLINE Link]. [Full Text].
  173. Tournigand C, Andre T, Achille E, et al.FOLFIRI followed by FOLFOX6 or the opposite sequence inward advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004 Jan 15. 22(2):229-37. [QxMD MEDLINE Link].
  174. Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin inwards patients with metastatic colorectal cancer:a pooled analysis of randomized trials. J Clin Oncol. 2008 Dec 20. 26(36):5910-7. [QxMD MEDLINE Link].
  175. Sehgal R, Lembersky BC, Rajasenan KK, et al. A Phase I/II Study of Capecitabine Given on a Week on/Week off Schedule Combined With Bevacizumab as well as Oxaliplatin for Patients With Untreated Advanced Colorectal Cancer. Clin Colorectal Cancer. 2011 Jun. 10(2):117-20. [QxMD MEDLINE Link].
  176. Rozyltrek (entrectinib) [packet insert]. South San Francisco, CA: Genentech USA, Inc. August, 2019. Available at [Full Text].



Vassiliki Liana Tsikitis, MD, MCR,MBA, FACS, FASCRS Professor of Surgery, Medical Director of Digestive Health Center, Department of Surgery, Chief of Division of Gastrointestinal and General Surgery, Oregon Health too Science University School of Medicine

Vassiliki Liana Tsikitis, MD, MCR, MBA, FACS, FASCRS is a fellow member of the next medical societies: Alpha Omega Alpha,American College of Surgeons, American Society of Clinical Oncology, American Society of Colon together with Rectal Surgeons, Association for Academic Surgery,European Society of Coloproctology, International Society for Digestive Surgery, International Society of Surgery, Pacific Coast Surgical Association, Society for Surgery of the Alimentary Tract,SWOG

Disclosure: Nothing to break.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-inward-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for job. for: Medscape.

Chief Editor

due north Joseph Espat, MD,MS, FACS Harold J Wanebo Professor of Surgery, Assistant Dean of Clinical Affairs, Boston University School of Medicine; Chairman, Department of Surgery, Director, Adele R Decof Cancer Center, Roger Williams Medical Center

N Joseph Espat, MD, MS, FACS is a fellow member of the next medical societies: Alpha Omega Alpha,American Association for Cancer Research, American College of Surgeons, American Medical Association, American Society for Parenteral together with EnteralNutrition, American Society of Clinical Oncology, Americas Hepato-Pancreato-Biliary Association, Association for Academic Surgery, CentralSurgical Association, Chicago Medical Society, International Hepato-Pancreato-Biliary Association, Pancreas Club, Sigma Xi, The ScientificResearch Honor Society, Society for Leukocyte Biology, Society for Surgery of the Alimentary Tract, Society of American Gastrointestinal together with Endoscopic Surgeons,Society of Surgical Oncology, Society of University Surgeons, Southeastern Surgical Congress, Southern Medical Association,Surgical Infection Society

Disclosure: Nothing to reveal.

Additional Contributors